Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects

31-12 4 1-12 1-12 1-12 1-6 1-6 77 1-12 771-12 771-12 1-12 1-12 1-12 1-12 1-12 1-12 1-12 81-381-381-381-35 4 5 Compounds of formula (I): wherein X is N, CH, CCF, or C(Caliphatic); Ris sulfonic acid, Caliphatic-sulfonyl, sulfonyl-Caliphatic, Caliphatic-sulfonyl-Caliphatic, Caliphatic-amino, R-sulfonyl...

Full description

Saved in:
Bibliographic Details
Main Authors Davis, Stephen Thomas, Dickerson, Scott Howard, Frye, Stephen Vernon, Harris, Philip Anthony, Hunter, III, Robert Neil, Kuyper, Lee Frederick, Lackey, Karen Elizabeth, Luzzio, Michael Joseph, Veal, James Marvin, Walker, Duncan Herrick
Format Patent
LanguageEnglish
Published 12.09.2006
Online AccessGet full text

Cover

More Information
Summary:31-12 4 1-12 1-12 1-12 1-6 1-6 77 1-12 771-12 771-12 1-12 1-12 1-12 1-12 1-12 1-12 1-12 81-381-381-381-35 4 5 Compounds of formula (I): wherein X is N, CH, CCF, or C(Caliphatic); Ris sulfonic acid, Caliphatic-sulfonyl, sulfonyl-Caliphatic, Caliphatic-sulfonyl-Caliphatic, Caliphatic-amino, R-sulfonyl, Rsulfonyl-Caliphatic, R-aminosulfonyl, R-aminosulfonyl-Caliphatic, R-sulfonylamino, R-sulfonylamino-Caliphatic, aminosulfonylamino, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl-Caliphatic, (R)-Arylamino, (R)-Arylsulfonyl, (R)-Aryl-aminosulfonyl, (R)-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, Ris hydrogen; and further wherein Rand Rare optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.